LQLena Quambusch

Lena Quambusch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lena Quambusch has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Isoformselektive Adressierung der Proteinkinase Akt durch Kovalent‐allosterische Inhibition

    by Giovanni Danilo D'ANgelo, Kosmas Alexandros Pervanidis, Ioannis Athanasiadis, Vladimir Lukianchikov, Andrea Scrima, Laura Depta, Sara Stier, Matthias P. Müller, Henner F. Farin, Lena Quambusch, et al.

    ZUSAMMENFASSUNG: Die Akt‐Familie der Serin/Threonin‐Kinasen spielt eine entscheidende Rolle bei zellulären Prozessen wie Proliferation, Zellüberleben und Metabolismus. Die drei Akt‐Isoformen (Akt1, Akt2 und Akt3) erfüllen dabei unterschiedliche physiologische Funktionen. Während die Dysregulation einzelner Isoformen mit Erkrankungen wie Krebs assoziiert ist, geht der klinische Einsatz unselektiver Akt‐Inhibitoren häufig mit erheblichen Nebenwirkungen einher. Geleitet von Röntgenkristallstrukturanalysen und Molekülmodellierung wurden strukturelle Merkmale der allosterischen Bindetaschen identifiziert, die die Isoformselektivität bestimmen, und gezielt für das strukturbasierte Design neuer Inhibitoren genutzt. Nach biologischer Charakterisierung erwiesen sich Inhibitoren mit einem Pyrazol‐Grundgerüst als die wirksamsten und selektivsten Akt2‐Inhibitoren, während Inhibitoren mit Pyridin‐Grundgerüst eine ausgeprägte Präferenz für Akt3 zeigten. Darüber hinaus wurden diese neuen Inhibitoren in patientenabgeleiteten kolorektalen Karzinomorganoiden evaluiert. Kokristallstrukturen boten Einblicke in die molekularen Grundlagen der Isoformselektivität und stimulierten das weitere Inhibitordesign. Diese Arbeit liefert damit einen Rahmen für die rationale Entwicklung isoformselektiver Wirkstoffe und unterstreicht deren Potenzial als chemische Sonden zur Aufklärung isoformspezifischer Signalfunktionen in komplexen biologischen Systemen.

  • Isoform‐Selective Targeting of Akt Through Covalent Allosteric Inhibition

    by Giovanni Danilo D'ANgelo, Kosmas Alexandros Pervanidis, Ioannis Athanasiadis, Vladimir Lukianchikov, Andrea Scrima, Laura Depta, Sara Stier, Matthias P. Müller, Henner F. Farin, Lena Quambusch, et al.

    The Akt family of serine/threonine kinases plays a crucial role in various cellular processes, including proliferation, survival, and metabolism. Three Akt isoforms (Akt1, Akt2, and Akt3) have distinct physiological roles, and while individual isoform dysregulation is disease‐linked, unselective Akt inhibition leads to side effects. Here, we report the development of selective covalent‐allosteric Akt inhibitors (CAAIs) targeting Akt2 and Akt3 while sparing Akt1. Guided by protein x‐ray crystallography and molecular modeling, key structural differences within the allosteric pockets of the isoforms were identified and exploited in a structure‐based design strategy. By stabilizing the inactive kinase conformation, CAAIs overcome the intrinsic selectivity limitations of ATP‐competitive inhibitors. After biological characterization, the pyrazole‐containing inhibitors emerged as the most potent and selective Akt2 inhibitors, while inhibitors with pyridines as an isoform‐selective element were predominantly targeting Akt3 selectively. Importantly, these new inhibitors were also evaluated in patient‐derived colorectal cancer organoids. Co‐crystal structures of inhibitors bound to an engineered construct mimicking the Akt2 allosteric pocket elucidated the molecular basis of isoform selectivity, guiding further optimization. This work not only establishes a framework for the development of isoform‐selective therapeutics but also highlights the potential for unraveling isoform‐specific functions in signaling pathways relevant to cancer biology.


  • Open Access

    Selective covalent-allosteric tools to dissect Akt2

    by Lena Quambusch, Danilo D’ANgelo, Tonia Kirschner, Maria Beerbaum, Laura Depta, Fabian Schnecke, Janina Niggenaber, Sven Brandherm, Joern Weisner, Matthias P. Mueller, et al.

    The protein kinase Akt and its isoforms play a crucial role in various diseases. Unique functions of the individual isoforms (Akt1, Akt2, Akt3) might be essential for survival in malignancies. Particularly for Akt2, it was reported that a knock-out led to diabetic phenotype and might be correlated with clinically adverse hyperglycemic effects observed in pan Akt-treatment. Enduring failure of Akt inhibitors in the clinic indicates the necessity for a thorough understanding of the underlying biology, preferably by using highly isoform-selective small molecules. Here we report the structure-guided development of Akt2-selective covalent-allosteric probe molecules, that can be successfully modified within a complex environment using biorthogonal chemistry. Thus, enabling first Akt2-specific pull-down studies and the use in functional studies, such as selective fluorescent labeling in cellular systems. These chemical probes expand our toolbox to dissect the critical questions of Akt2’s function in health and disease, thereby paving the way for novel therapeutic strategies based on thorough mechanistic insights.

  • Open Access

    Cellular model system to dissect the isoform-selectivity of Akt inhibitors

    by Lena Quambusch, Laura Depta, Ina Landel, Melissa Lubeck, Tonia Kirschner, Jonas Nabert, Niklas Uhlenbrock, Jörn Weisner, Michael Kostka, Laura M. Levy, et al.

    The protein kinase Akt plays a pivotal role in cellular processes. However, its isoforms’ distinct functions have not been resolved to date, mainly due to the lack of suitable biochemical and cellular tools. Against this background, we present the development of an isoform-dependent Ba/F3 model system to translate biochemical results on isoform specificity to the cellular level. Our cellular model system complemented by protein X-ray crystallography and structure-based ligand design results in covalent-allosteric Akt inhibitors with unique selectivity profiles. In a first proof-of-concept, the developed molecules allow studies on isoform-selective effects of Akt inhibition in cancer cells. Thus, this study will pave the way to resolve isoform-selective roles in health and disease and foster the development of next-generation therapeutics with superior on-target properties.